News

TB Alliance makes series of announcements regarding new initiatives to combat childhood TB

TB Alliance, an international non-profit whose mission is to develop better and more affordable drugs against tuberculosis, made three announcements on World TB Day demonstrating their commitment to combating childhood TB.


Web portal for childhood TB

On World TB Day, the TB Alliance in partnership with the World Health Organization and UNITAID launched a Web Portal (http://www.tballiance.org/children/) dedicated to providing valuable resources for the fight against childhood tuberculosis. Currently, children infected with TB are administered adult drugs that are either crushed or split. These drug regimens are neither correctly-dosed nor properly formulated, and introduce an unwanted variability to treatment. Furthermore, treatment may last 6-30 months, which causes problems with adherence and increases the likelihood of drug resistance.

The new Web Portal launched by TB Alliance aims to address these problems with childhood tuberculosis. The portal provides information on what is known about childhood TB, including information on present challenges, advocacy material, and resources on key markets and regulatory issues.

For more information on the childhood TB web portal, read the press release here

Clinical study of TB treatment in infants

TB Alliance and the Desmond Tutu TB Center, an academic research center based out of the University of Stellenbosch in South Africa have announced a clinical study that will measure the efficacy of TB treatment in 30 infected infants. Data from the study will elucidate whether distinct drug regimens are required to treat drug-sensitive TB in children weighing less than 5kg.

For more information on the clinical study, read the press release here

Advisory group to help end neglect of childhood TB

TB Alliance established a new advisory group that will help guide the organization’s effort to combat childhood tuberculosis. The advisory group consists of prominent officials with backgrounds ranging from healthcare, international development, and drug-discovery in big pharma.

For more information on the new advisory group, click here

More information on childhood TB

World TB Day Lancet Viewpoint: child survival linked to TB control

Tuberculosis Affects Children More Than Previously Thought

New childhood TB cases double earlier estimates

More News
17 Sep 2019
Earlier this month, the NIH announced two new Funding Opportunity Annoucnements (FOAs) on the topic of Myeloid-Derived Suppressor Cells (MDSC) as potential therapeutic targets in TB/HIV co-infected patients. The purpose of these FOAs is to invite applications for support of innovative clinical,...
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...